MMB has been evaluated for the treatment of metastatic PDA, EGFR- or K-RAS-activated NSCLC (Table 3) [18, 261–267]; however, oral MMB at doses of 100-300 mg QID did not show any clinically meaningful benefit, neither as monotherapy nor in combination with other drugs. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.